BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Change in Inventory of -$222000.0 for Q1 2026, down 500.0% year-over-year from $55500.0 in Q1 2025, and down 184.41% quarter-over-quarter from $263000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Change in Inventory history runs 5 years deep, the most recent figure standing at -$222000.0 for Q1 2026.
- In Q1 2026, Change in Inventory fell 500.0% year-over-year to -$222000.0; the TTM figure through Mar 2026 stood at -$142000.0 (up 92.1% YoY), while the FY2025 annual figure was $43000.0, up 103.28% from the prior year.
- Change in Inventory for Q1 2026 stood at -$222000.0, down from $263000.0 in the prior quarter.
- The five-year high for Change in Inventory was $713000.0 in Q2 2022, with the low at -$1.2 million in Q3 2024.
- The 5-year median for Change in Inventory is -$27000.0 (2023), against an average of $29411.8.
- Peak annual rise in Change in Inventory reached 1457.58% in 2024, while the deepest fall reached 3033.33% in 2024.
- BioXcel Therapeutics' Change in Inventory stood at $577000.0 in 2022, then plunged by 104.68% to -$27000.0 in 2023, then tumbled by 3033.33% to -$846000.0 in 2024, then surged by 131.09% to $263000.0 in 2025, then plunged by 184.41% to -$222000.0 in 2026.
- Business Quant data shows BTAI's Change in Inventory at -$222000.0 in Q1 2026, $263000.0 in Q4 2025, and -$47000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -59.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 23.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -209.58 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 17.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 99.50 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 6.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.30 Mn | 24.30 Mn | 160,000.00 | -17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17,000.00 |
| Jun 30, 2026 | -17,000.00 |
| Mar 31, 2026 | -222,000.00 |
| Mar 31, 2026 | -222,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | -846,000.00 |
| Dec 31, 2024 | -846,000.00 |
| Sep 30, 2024 | -1.16 Mn |
| Sep 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |